VJHemOnc is committed to improving our service to you

COMy 2020 | Treating GvHD with proteasome inhibitors

VJHemOnc is committed to improving our service to you

Arnon Nagler

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the drugs that have been approved to treat graft versus host disease (GvHD) after transplantation. One option is to treat patients with proteasome inhibitors, such as bortezomib and carfilzomib. In an early-stage study, carfilzomib has shown a good response to prevent GvHD. However, the study compared responses to historical controls. Therefore, carfilzomib needs to be evaluated in a randomized setting. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter